NY-UPFLEX
20.12.2022 15:01:37 CET | Business Wire | Press release
Upflex, the premier provider of hybrid workspace solutions, is bringing yet another successful year of company growth to a close. This momentum — a testament to flex as a new workplace standard — includes a 400% increase in Upflex’s customer base. Global corporations such as Willis Towers Watson, HH Global, and Schneider Electric, as well as leading tech firms such as Snowflake, Alation and Gympass are among those that have chosen Upflex as their hybrid workspace partner. To serve a fast-growing global demand, Upflex has increased its employee headcount by more than 200% with new hires across 12 countries.
Upflex, which was founded in 2018 by CEO Christophe Garnier and CPO Ginger Dhaliwal, builds technology and solutions to connect companies, space providers, and brokers in one cooperative ecosystem for more manageable, more sustainable flexible work. This year, with flexible workspace options being more important than ever, the company’s platform and flex workspace usage data have been in high demand.
“Since Upflex’s inception, providing a more efficient, flexible, and sustainable way of working has been our core mission,” said Christophe Garnier, CEO and co-founder of Upflex. “In 2022, we have seen that companies across the world are embracing hybrid work, and that they need better solutions for adopting and managing it. We’ve also seen in recent months that enterprise companies are increasingly concerned with cost savings moving toward a potential economic recession, and I’m thrilled that Upflex can be part of the solution for these employers to create new workspace efficiencies that cut real estate costs, so they don’t have to cut their people.”
Earlier this year, Upflex grew its EMEA presence with the acquisition of WorkClub, a UK-based coworking space aggregator, and entered an exclusive, strategic global partnership with WeWork, adding hundreds of WeWork locations to Upflex’s network of thousands of bookable desks, meeting rooms, and private offices around the world. As the sole aggregator of WeWork inventory, Upflex and WeWork clients benefit from enhanced coverage and optionality in workspaces. In May, Upflex announced a $30 million Series A round led by WeWork, with participation from top strategic and venture funds, including Newmark, Cushman & Wakefield, Industry Ventures, Inertia Ventures and GPO Fund.
Other 2022 milestones for Upflex include:
- Being selected as a finalist in the most prestigious awards in proptech: CRETech’s Real Estate Tech Awards;
- Expanding from 74 to 120 countries, including China, Japan, Indonesia, and Brazil, and increasing the company’s presence from 875 to 1,250 cities;
- Expanding Upflex's global workspace network from 4,900 to 10,000 workspace locations and adding 325 operators reaching a total of 1,350 operators;
- Launching a major partnership with brokerage firm Newmark to power Optality, a white-labeled version of the Upflex app. This partnership expands upon Upflex’s impressive roster of brokerage partners, including Colliers.
- Expanding its White Label offering to global flex operators including the UK’s largest flex operator Landmark, to make booking and payment instant and seamless for all their users across nearly 50 locations in nine major UK cities;
- Partnering with Chief Brand Advisory (CBA) in October to launch a reimagined brand strategy, in tandem adding CBA’s Founder, Brad Kay, as an investor and advisor;
- Continuing its partnership with the non-profit Trees for the Future to plant a tree for every desk booked on its platform. So far, Upflex has planted over 20,000 trees, a significant impact on reducing global carbon emissions and supporting its core mission of sustainability.
“Upflex will continue to invest a tremendous amount of resources to advance the development of our best-in-class hybrid work technology,” said Ginger Dhaliwal, CPO and co-founder of Upflex. “As companies look to make more informed real estate decisions, the future of the evolving workplace lies in utilization data. With Upflex’s real-time employee analytics, companies are able to be proactive in their workplace planning as they work to build sustainable strategies that serve their business, their people, and the planet.”
About Upflex:
Upflex (upflex.com) is a workspace intelligence platform bringing together people, places, and data to deliver the right workplace strategies for forward-thinking companies and their employees, from startups to the Fortune 100. Founded in 2018 as a co-working aggregator and booking platform, the company recently raised $30MM in Series A funding, forged an exclusive partnership with WeWork, and is expanding its operations to strengthen its global network. Today, Upflex has evolved beyond an aggregator, connecting companies, space providers and brokers to create an ecosystem of flexible and sustainable workspace experiences. Upflex leverages technology, services, and insights to make finding and managing global workspaces simple, smarter, and more agile.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221219005473/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
